Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Go back to Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer| (NASDAQ: ARVN) | Delayed: 8.05 -0.09 (1.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.14 | 52 Week High | $ | |||
| Open | $7.99 | 52 Week Low | $ | |||
| Day High | $8.48 | P/E | N/A | |||
| Day Low | $7.97 | EPS | $ | |||
| Volume | 677,158 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.04 -0.68 (2.75%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.72 | 52 Week High | $37.39 | |||
| Open | $24.80 | 52 Week Low | $28.25 | |||
| Day High | $25.11 | P/E | 14.57 | |||
| Day Low | $23.93 | EPS | $1.65 | |||
| Volume | 76,926,336 | |||||
